{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:08:29Z","timestamp":1768450109413,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012101","name":"Italian Society of Hematology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012101","name":"Italian Society of Experimental Hematology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012101","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Italian Group for Bone Marrow Transplantation"},{"name":"Mundipharma"},{"name":"Janssen Cilag"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.clml.2014.07.002","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T17:32:08Z","timestamp":1405445528000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma)"],"prefix":"10.1016","volume":"15","author":[{"given":"Corrado","family":"Tarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atto","family":"Billio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.07.002_bib1","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.clml.2014.07.002_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib3","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on\u00a0rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BJM"},{"key":"10.1016\/j.clml.2014.07.002_bib5","first-page":"460","article-title":"The NIH Consensus Development Program: the evolution of guidelines","volume":"12","author":"Ferguson","year":"1996","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clml.2014.07.002_bib6","series-title":"Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes","author":"Delbecq","year":"1975"},{"key":"10.1016\/j.clml.2014.07.002_bib7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"Somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.07.002_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib11","first-page":"783","article-title":"Prognosis of follicular lymphomas: a predictive model based on a retrospective analysis of 987 cases","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2014.07.002_bib13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.07.002_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.07.002_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.07.002_bib18","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/cncr.26708","article-title":"Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation","volume":"118","author":"Ferrario","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00277-010-1067-1","article-title":"Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)","volume":"90","author":"Ferrario","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.07.002_bib20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3109\/10428194.2012.747679","article-title":"Retreatment with bendamustine-containing regimens in patients with relapsed\/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions","volume":"54","author":"Weide","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.07.002_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma\u2014a multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"Koenigsmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.07.002_bib22","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib23","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable response in relapsed or refractory indolent non-Hodgkin lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib24","article-title":"Bendamustine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas\u2014final results of the randomized phase III study NHL-22003 on behalf of the StiL","volume":"116","author":"Rummel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jcp.40.6.642","article-title":"Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens","volume":"40","author":"Melo","year":"1987","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2014.07.002_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-2141.2003.04449.x","article-title":"Patterns of bone marrow involvement in 58 patients presenting [with] primary splenic marginal zone lymphoma with or without circulating villous lymphocytes","volume":"122","author":"Audouin","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.002_bib27","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","article-title":"Splenic marginal zone lymphoma with or without villous lymphocytes: hematologic findings and outcomes in a series of 57 patients","volume":"101","author":"Iannitto","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.002_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.07.002_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases","volume":"78","author":"Mulligan","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.002_bib31","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clml.2014.07.002_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.07.002_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4986.4986","article-title":"Rituximab, either as single agent or in combination, is superior to other treatments in terms of response rate and progression-free survival (PFS) in patients with splenic marginal zone lymphoma (SMZL)","volume":"118","author":"Marin-Niebla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.002_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2014.07.002_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/annonc\/mdp395","article-title":"Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)","volume":"21","author":"Cervetti","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib39","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"185","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","author":"Isaacson","year":"2008"},{"key":"10.1016\/j.clml.2014.07.002_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.0953-0673.1996.00289.x","article-title":"Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies","volume":"10","author":"Dickey","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clml.2014.07.002_bib41","first-page":"1148","article-title":"Evaluation of Helicobacter pylori in gastric MALT-type lymphoma: differences between histologic and serologic diagnosis","volume":"12","author":"Eck","year":"1999","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2014.07.002_bib42","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H.\u00a0pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2014.07.002_bib43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/gut.2007.123729","article-title":"Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation","volume":"56","author":"Nakamura","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.clml.2014.07.002_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/oxfordjournals.annonc.a058869","article-title":"Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma","volume":"5","author":"Rohatiner","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib45","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/gut.52.6.912","article-title":"Paris staging system for primary gastrointestinal lymphomas","volume":"52","author":"Ruskone-Fourmestraux","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.clml.2014.07.002_bib46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1054\/bjoc.2000.1308","article-title":"Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma","volume":"83","author":"Raderer","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib47","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1053\/gast.2000.19579","article-title":"Primary gastric B-cell lymphoma: results of a prospective multicenter study. The Germane Austrian Gastrointestinal Lymphoma Study Group","volume":"119","author":"Fischbach","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2014.07.002_bib48","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1200\/JCO.2005.04.031","article-title":"Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96)","volume":"23","author":"Koch","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0002-9610(00)00295-6","article-title":"Management and long-term results of surgery for localized gastric lymphomas","volume":"179","author":"Vaillant","year":"2000","journal-title":"Am J Surg"},{"key":"10.1016\/j.clml.2014.07.002_bib50","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2001.19.18.3874","article-title":"Primary gastrointestinal non-Hodgkin lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma: results of the prospective German Multicenter Study GIT NHL 01\/92","volume":"19","author":"Koch","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000658-199801000-00007","article-title":"The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma","volume":"227","author":"Kodera","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.clml.2014.07.002_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/SLA.0b013e3181582364","article-title":"Long term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment","volume":"247","author":"Kuo","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.clml.2014.07.002_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.radonc.2008.02.012","article-title":"Long-term results of stomach-conserving therapy in gastric MALT lymphoma","volume":"87","author":"Vrieling","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib54","first-page":"430","article-title":"Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma","volume":"49","author":"Fischbach","year":"2011","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.clml.2014.07.002_bib55","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/ajg.2009.314","article-title":"Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis","volume":"104","author":"Zullo","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clml.2014.07.002_bib56","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.clml.2014.07.002_bib57","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3748\/wjg.v16.i17.2158","article-title":"Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma","volume":"16","author":"Park","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2014.07.002_bib58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.002_bib59","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gut.52.11.1656","article-title":"Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma","volume":"52","author":"Copie-Bergman","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.clml.2014.07.002_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gut.53.1.34","article-title":"Long term outcome of patients with gastric marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series","volume":"53","author":"Fischbach","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.clml.2014.07.002_bib61","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1998.16.5.1916","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone","volume":"16","author":"Schechter","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib62","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.radonc.2008.12.004","article-title":"Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma","volume":"90","author":"Tomita","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib64","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib65","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2005.05.660","article-title":"Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy","volume":"23","author":"Levy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000079502","article-title":"Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma","volume":"66","author":"Streubel","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2014.07.002_bib67","first-page":"CD009045","article-title":"Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia","volume":"9","author":"Vidal","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2014.07.002_bib68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:22:1:057","article-title":"Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial","volume":"22","author":"Aviles","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib70","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib72","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.002_bib73","doi-asserted-by":"crossref","unstructured":"Aguiar-Bujanda D, Llorca-M\u00e1rtinez I, Rivero-Vera JC, et\u00a0al. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone [e-pub ahead of print]. Hematol Oncol http:\/\/dx.doi.org\/10.1002\/hon.2105, accessed: July 8, 2014.","DOI":"10.1002\/hon.2105"},{"key":"10.1016\/j.clml.2014.07.002_bib74","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mds644","article-title":"Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database","volume":"5","author":"Olszewski","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib75","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/annonc\/mds623","article-title":"Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study","volume":"24","author":"Wirth","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib76","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.07.002_bib77","unstructured":"NCCN Guidelines, version 1, 2014: Non-Hodgkin's Lymphomas. Available at: http:\/\/www.nccn.org\/professionals\/default.aspx. Accessed: July 8, 2014."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:40Z","timestamp":1761870340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S2152265014002626"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}